PT-141 10mg

Overview

PT-141 (Bremelanotide) is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (a-MSH). It is a cyclic heptapeptide and non-selective melanocortin receptor agonist, with primary activity at MC3R and MC4R -- receptors expressed in the central nervous system and involved in sexual response pathways. Bremelanotide was approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the only approved melanocortin-based pharmaceutical. Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 acts centrally through hypothalamic melanocortin circuits -- representing a fundamentally different mechanism in sexual function research.

Primary Research Areas

• Melanocortin receptor pharmacology -- MC3R and MC4R binding affinity, selectivity profiling, and downstream cAMP signaling cascade characterization
• CNS pathway mapping -- hypothalamic and limbic system activation patterns in sexual response models, including fMRI-based receptor mapping studies
• Autonomic nervous system -- erectile response pathways independent of NO/cGMP mechanisms, representing a novel pharmacological target
• Melanocortin system biology -- role of MC receptors in energy homeostasis, inflammation, and appetite regulation beyond sexual function
• Comparative pharmacology -- structure-activity relationships between PT-141, Melanotan I, and Melanotan II at melanocortin receptor subtypes

PT-141 evolved from Melanotan II research conducted by Dr. Mac Hadley and colleagues at the University of Arizona in the 1980s-90s.